Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA

Slides:



Advertisements
Similar presentations
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Advertisements

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
A Controlled Trial of Renal Denervation for Resistant Hypertension
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA
Dr John Cox Diabetes in Primary Care Conference Cork
The SPRINT Research Group
McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL
A.M. Thompson, T.G. Pickering  Kidney International 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Intensive Hemodialysis, Treatment Complications and Tolerability
Robert C. Stanton, MD  American Journal of Kidney Diseases 
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Flowchart of participants
Copyright © 2000 American Medical Association. All rights reserved.
by Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B
Intensive Hemodialysis, Treatment Complications and Tolerability
Intensive Hemodialysis: Applied Clinical Practice
McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL
Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA
Volume 62, Issue 3, Pages (September 2002)
Intensive Hemodialysis and Health-related Quality of Life
Intensive Hemodialysis and Health-related Quality of Life
Hypertension in Dialysis Patients
Systolic Blood Pressure Intervention Trial (SPRINT)
Intensive Hemodialysis and Potential Risks with Increasing Treatment
Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA
Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.
Management of hypertension in patients with chronic kidney disease
Hypertension in Dialysis Patients
Intensive Hemodialysis and Potential Risks with Increasing Treatment
Intensive Hemodialysis and Health-Related Quality of Life
The risk of hospitalization and modality failure with home dialysis
Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective  J. Michael Lazarus, MD, Raymond M. Hakim,
Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion  Matthew.
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
Erratum Regarding “Ultrasound Monitoring to Detect Access Stenosis in Hemodialysis Patients: A Systematic Review” (Am J Kidney Dis. 2008;51(4): ) 
Volume 82, Issue 1, Pages (July 2012)
Volume 80, Issue 10, Pages (November 2011)
Vitality Measured as Self-reported Energy Level and Clinical Outcomes in Hemodialysis Patients: The Japanese Dialysis Outcomes and Practice Pattern Study.
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Volume 76, Issue 10, Pages (November 2009)
Appendix 1: methods used for guideline development
Iain C. Macdougall, MD  American Journal of Kidney Diseases 
Michael Copland, MD, Paul Komenda, MD, Eric D
Volume 91, Issue 5, Pages (May 2017)
This Month in AJKD American Journal of Kidney Diseases
Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study  Eric D.
The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Volume 61, Issue 6, Pages (June 2002)
Volume 62, Issue 3, Pages (September 2002)
Peter A. McCullough, MD, MPH, Christopher T. Chan, MD, Eric D
Intensive Hemodialysis and Potential Risks With Increasing Treatment
George L. Bakris, MD, John M. Burkart, MD, Eric D
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target    American.
Volume 75, Issue 5, Pages (March 2009)
Better Management of Volume with Intensive Hemodialysis
Volume 73, Issue 8, Pages (April 2008)
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related.
This Month in AJKD American Journal of Kidney Diseases
Volume 60, Issue 3, Pages (September 2001)
Volume 75, Issue 1, Pages (January 2009)
American Journal of Kidney Diseases
Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Intensive Hemodialysis, Blood Pressure and Antihypertensive Medication Use Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. American Journal of Kidney Diseases, Volume 68, Issue 5, S15 - S23. AdvancingDialysis.org

of conventional hemodialysis patients Despite substantial use of multiple antihypertensive agents, most hemodialysis patients have elevated pre-dialysis blood pressure.1 Chapter 2, Figure 1:2 Distribution of pre-dialysis systolic blood pressure in the Dialysis Outcomes and Practice Patterns Study Practice Monitor, December 2015.1 Over 60% of conventional hemodialysis patients >140 mmHg SBP 1The DOPPS Practice Monitor. http://www.dopps.org/DPM/. Accessed May 20, 2015. 2Bakris GL, JM Burkhart, Weinhandl ED, McCullough PA, Kraus MA. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016;68(5)(suppl 1):S15-S23. AdvancingDialysis.org

Multiple randomized clinical trials show intensive hemodialysis significantly lowers blood pressure.1,2,3 Chapter 2, Figure 2:4 Effects of intensive versus conventional hemodialysis on pre-dialysis systolic blood pressure in the FHN Daily Trial,1 the FHN Nocturnal Trial,2 and the Canadian trial of nocturnal hemodialysis.3 Estimated treatment effects (solid dots) and associated 95% confidence intervals (solid lines) are displayed at the bottom. 1FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300. doi:10.1056/NEJMoa1001593. 2Rocco MV, Lockridge RS, Beck GJ, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int. 2011;80(10):1080-1091. doi:10.1038/ki.2011.213. 3Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298(11):1291-1299. doi:10.1001/jama.298.11.1291. 4Bakris, G.L., Burkart, J.M., Weinhandl, E.D., McCullough, P.A., Kraus, M.A. Intensive hemodialysis, blood pressure, and antihypertensive medication use. Am J Kidney Dis. 2016;68:S15–S23. -10 mmHg -8 mmHg -11 mmHg AdvancingDialysis.org

In the FHN Daily Trial, the number of antihypertensive medications per patient declined from 2.2 to 1.4.1 In trials of nocturnal hemodialysis, the number of antihypertensive medications per patient decreased similarly.2 Chapter 2, Figure 3:3 Mean number of prescribed antihypertensive medications at baseline, at month 4, and at month 12 of the FHN Daily Trial.1 Dashed bars span one standard deviation above and below the mean. 36% Decrease at month 12 1Kotanko P, Garg AX, Depner T, et al. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. Hemodial Int Int Symp Home Hemodial. 2015;19(3):386-401. doi:10.1111/hdi.12255. 2Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs. conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298(11):1291-1299. doi:10.1001/jama.298.11.1291. 3Bakris, G.L., Burkart, J.M., Weinhandl, E.D., McCullough, P.A., Kraus, M.A. Intensive hemodialysis, blood pressure, and antihypertensive medication use. Am J Kidney Dis. 2016;68:S15–S23. AdvancingDialysis.org